Ultragenyx Pharmaceutical Inc. has agreed to sell a special voucher for $210 million.

Oct 7, 2026, 9:05 AM ETDealRead the original at SEC EDGAR

Good for RARE

Ultragenyx agreed to sell its voucher for $210 million in cash at closing. NIH receives 20% of the gross proceeds, but the cash sale still favors the company if it closes.

RARE · Ultragenyx Pharmaceutical Inc.

AI read · Good for RARE

The AI's read

That payment could give Ultragenyx more cash for its work or other needs. The company must pay NIH 20% of the sale proceeds, and the deal still needs to clear closing conditions. The cash still supports the company, but it arrives only if the sale closes.

Get alerts for RARE

Follow Ultragenyx Pharmaceutical Inc. (RARE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RARE

Free on the App Store and Google Play, or on the web.